Skip to main content
PMC home page
Nature Portfolio logoLink to Nature Portfolio
. 2024 Jan 31;30(5):1505. doi: 10.1038/s41591-024-02835-9

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Karim Fizazi 1,✉,#, Arun A Azad 2, Nobuaki Matsubara 3, Joan Carles 4, Andre P Fay 5, Ugo De Giorgi 6, Jae Young Joung 7, Peter C C Fong 8,9, Eric Voog 10, Robert J Jones 11, Neal D Shore 12, Curtis Dunshee 13, Stefanie Zschäbitz 14, Jan Oldenburg 15, Dingwei Ye 16, Xun Lin 17, Cynthia G Healy 18, Nicola Di Santo 19, A Douglas Laird 17, Fabian Zohren 20, Neeraj Agarwal 21,✉,#
PMCID: PMC11108769  PMID: 38297094

Correction to: Nature Medicine 10.1038/s41591-023-02704-x, published online 4 December 2023.

In the version of the article initially published, the top right label in Fig. 4e, now reading “Median PSF2”, was a duplicate of the top right label in Fig. 4d. The error has been corrected in the HTML and PDF versions of the article.

Contributor Information

Karim Fizazi, Email: karim.fizazi@gustaveroussy.fr.

Neeraj Agarwal, Email: neeraj.agarwal@hci.utah.edu.

Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES